Chelsea Therapeutics announces untrodden investigator to out period II clinical work of Droxidopa
Chelsea Therapeutics Universal, Ltd. (Nasdaq:CHTP) announced that a creative investigator-led end II clinical reading of Droxidopa, an uttered counterfeit herald of norepinephrine, has been initiated in continuing languor syndrome (CFS).
CFS is a complex and crippling fray characterized pre-eminently extraordinarily tire that is not improved nearby surplus. In combining to exhaust, patients with CFS face symptoms, compare favourably with to that of fibromyalgia including, proclivity, muscle suffering, impaired respect and concentration. Droxidopa has been shown to renovate symptoms of weaken, eye and concentration in neurogenic orthostatic hypotension associated with a brand of conditions including Parkinson’s complaint, multiple approach atrophy and uncontaminated autonomic fizzle. Droxidopa is also being deliberate in an persistent Development II checking in fibromyalgia where, during an interim critique, an self-assured figures monitoring panel platitude substantive efficacy in multiple treatment arms.
Help-Medical.net finds at this phrases:
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
